Multi-Omics Aging Clock

• Multi-omics aging clocks are predictive models that combine data from transcriptomics, epigenomics, metabolomics, imaging, and clinical phenotypes to estimate biological age and stratify risk.
• They employ advanced feature engineering and machine learning methods (e.g., LightGBM, deep neural networks) to harness non-redundant signals across multiple biological layers.
• Clinical applications include personalized health monitoring and risk stratification, achieving high predictive accuracy (e.g., MAE 3.3–5.1 years) compared to single-omics models.

A multi-omics aging clock is a predictive model that integrates multiple classes of molecular and physiological data—such as transcriptomics, epigenomics, metabolomics, lipidomics, the microbiome, medical imaging, and clinical phenotypes—to estimate biological age (BA), characterize inter-individual heterogeneity, and stratify risk for future disease. Unlike single-omics clocks constrained to a specific molecular layer, multi-omics frameworks leverage the shared and distinct signals across biological systems, providing a broader and higher-resolution quantification of organismal aging dynamics.

1. Data Modalities and Feature Engineering

Multi-omics aging clocks rely on high-dimensional data spanning several molecular and clinical axes:

• Transcriptomics: Bulk RNA-seq (e.g., from PBMCs), capturing expression of tens of thousands of genes. Workflow includes quality filtering, TMM normalization (edgeR), followed by BH-FDR filtering for age-correlation and LightGBM-based SHAP value selection.
• Lipidomics and Metabolomics: LC-HRMS and NMR-based quantification of hundreds of lipid species and small molecules; normalization with internal standards or proprietary pipelines, and downstream filtering as above.
• Microbiome: Gut (e.g., 736 ASVs via 16S V3–V4) and oral (2,087 ASVs via 16S V4) taxonomic composition; processed by DADA2/QIIME2 denoising, species-level abundance tables (SILVA/HOMD reference), absence of batch correction required in uniform pipelines.
• Epigenomics: DNA methylation β-values, often from Illumina 450K arrays, centered and normalized, with CpG sites filtered for highest |ρ| correlation with age and confirmed via BorutaShap.
• Imaging: T1-weighted brain MRI (e.g., FreeSurfer/FSLVBM-extracted gray matter densities), harmonized across acquisition centers, spatially standardized.
• Clinical Covariates: System-level variables (cardiometabolic, immune, frailty, mental health, etc.), typically encoded as integers/factor levels; used in both feature construction and confounder adjustment.

Preprocessing minimizes noise and batch effects, removes features with excessive missingness, and applies sequential filtering via statistical correlation and predictive modeling (e.g., LightGBM SHAP values), ensuring selection of biologically and statistically robust inputs (Li et al., 14 Oct 2025, Jiang et al., 10 Nov 2025, Mateus et al., 2024).

2. Predictive Modeling Algorithms and Training Strategies

Multi-omics clocks employ diverse machine learning frameworks tailored to the structure of each data modality:

• Tree-ensemble models: LightGBM, employed for nonlinear molecular feature integration, trained using nested 10-fold cross-validation, with hyperparameter optimization (learning rate, max_depth, num_leaves, ℓ₁/ℓ₂ penalties) and early stopping on held-out validation sets. Objective functions are mean squared error (MSE) or squared error loss; feature contributions are interrogated through SHAP values (Li et al., 14 Oct 2025).
• Linear penalized regression: LASSO and Elastic Net serve as interpretable baselines, formalized as

$$\mathcal{L}(w,b) = \frac{1}{n}\sum_{i=1}^n (y_i - X_i w - b)^2 + \lambda\left(\alpha \|w\|_1 + \tfrac{1-\alpha}{2}\|w\|_2^2\right),$$

with penalty terms to induce sparsity and prevent overfitting, especially in high-dimensional CpG or gene-expression inputs (Li et al., 14 Oct 2025).

• TabPFN: Applied in recent multi-modal epigenetic/phenotypic ensemble frameworks (e.g., EpiCAge), exploiting Bayesian in-context learning and ensemble stacking. Base clocks are fit to selected features or combined features; meta-fusion utilizes both first-layer predictions and dimension-reduced or raw features (Jiang et al., 10 Nov 2025).
• Deep neural networks (DNNs): 3D CNNs trained on brain MRI for "BrainAge" estimation in federated settings, where local model updates are aggregated via FedAvg to maintain privacy. Training is performed across harmonized datasets, with performance evaluated by out-of-sample MAE (Mateus et al., 2024).

Model selection is governed by external performance metrics and comparative analysis with existing clocks (Horvath, Hannum, PhenoAge). For multi-modal models, early- and late-fusion strategies, ensemble averaging, and skip-connections to raw features are systematically explored to capture non-redundant signals from each data layer (Jiang et al., 10 Nov 2025, Mateus et al., 2024).

3. Quantitative Performance and Biological Age Acceleration

Performance evaluation employs standard regression and risk-prediction metrics:

• Accuracy metrics: Pearson’s $R$, coefficient of determination ($R^2$), RMSE, MAE, and median absolute error, quantified on cross-validated and held-out cohorts. For instance, LightGBM-based omics clocks achieve MAE values between 3.3–5.1 years, with $R$ up to 0.91 (gut microbiome) and $R^2$ up to 0.83 (Li et al., 14 Oct 2025).
• Comparative model accuracy: EpiCAge-TabPFN outperforms all tested epigenetic (e.g., Horvath, Hannum) and phenotypic clocks, reducing RMSE/MAE by ~62% versus epigenetic baselines and ~36% versus phenotypic clocks, and increasing $R^2$ by ~0.6 on external cohorts (Jiang et al., 10 Nov 2025).
• Multi-modal synergy: Combining orthogonal biological age scores (e.g., MRI-based BrainAge and metabolomics-based MetaboAge) in a federated learning framework yields significantly improved mortality prediction compared to either modality alone. Hazard ratios for all-cause mortality are significantly >1 for both $\Delta$BAG and $\Delta$MAG, and the joint model stratifies survival more effectively (Mateus et al., 2024).
• Biological Age Acceleration: $\mathrm{AgeAccel}_i = \hat{y}_i - y_i$ is extracted as the clock residual and used in Cox proportional hazards modeling. Gut- and oral-microbiome AgeAccel show strong prediction of disease incidence (OR 1.20–1.35 per +1 year for 14/16 non-cancer diseases), and multi-omics AgeAccel is linearly associated with accumulated multimorbidity in late life ($\beta=0.12$ diseases per +1 y; $p=3\times10^{-6}$) (Li et al., 14 Oct 2025, Jiang et al., 10 Nov 2025).

4. Biological Insights and System-Level Archetypes

Multi-omics integration enables the discrimination of aging subtypes via unsupervised learning:

• Clustering and archetype discovery: Fuzzy C-means clustering ($m=1.5$; $K=6$ by elbow/silhouette/Xie–Beni indices) applied to feature trajectories identifies distinct biological subtypes. Accelerated-aging clusters are typified by steep mid-life molecular transitions in microbiome, immune, and lipid axes; decelerated-aging clusters maintain molecular homeostasis into later life.
• Pathway enrichment: Accelerated clusters are driven by immune (e.g., IL7R, CD28, CXCL10, LAG3), metabolic (glycine, leucine), and microbiota (Bacteroides vulgatus) pathways with GO enrichments in T cell activation and neutrophil degranulation. Decelerated clusters are enriched for antioxidant metabolites and small-molecule processes (GO:0044281, GO:0034599) (Li et al., 14 Oct 2025).
• Sex differences and trajectories: Aging waves are sex-specific: females exhibit early peaks in metabolome/lipidome (50–55 y, coincident with menopausal transition), while males show delayed peaks (60–65 y) alongside sharper oral-microbiome changes (Li et al., 14 Oct 2025).
• Resilience and dynamic networks: Dynamical network analyses (autoregressive SF models) decompose multiple biological ages into slow modes, with the principal slow eigendirection quantifying resilience to physiological perturbations on human-lifespan timescales. Physiological age emerges as a central network node, and the slowest mode (z₁) correlates strongly with both CA and future frailty index change (Pridham et al., 2023).

5. Methodological Advances and Implementation Challenges

Construction and deployment of multi-omics clocks present unique analytical and translational challenges:

• Dimensionality reduction and feature selection: Principal component analysis (PCA), autoencoders, and regularized regression (LASSO, Elastic Net) control overfitting and reduce noise in high-dimensional layers prior to integration or network modeling (Jiang et al., 10 Nov 2025, Pridham et al., 2023).
• Cross-platform and batch harmonization: Uniform experimental protocols limit batch effects; in federated or multi-cohort studies, harmonized preprocessing (e.g., imaging, metabolomics) is essential. Some pipelines bypass batch correction if all samples derive from coordinated platforms (Li et al., 14 Oct 2025, Mateus et al., 2024).
• Privacy-preserving learning: Federated learning (FedAvg) allows DNNs to be trained on medical images across centers without sharing raw data, enhancing generalizability and real-world cohort coverage (Mateus et al., 2024).
• Longitudinal modeling and network inference: Stochastic finite-difference (SF) models accommodate variable sampling intervals and allow noise estimation. Block-sparse hierarchical SF models can capture cross-talk between omics layers and quantify network structure (e.g., $W^{(k\to\ell)}$), supporting mechanistic interpretation (Pridham et al., 2023).

6. Clinical Translation and Future Directions

Multi-omics aging clocks demonstrate substantial potential for clinical and public-health applications:

• Personalized health monitoring: Integrative clocks support individualized trajectory analysis and early detection of deviations from homeostatic aging, facilitating healthspan extension strategies (Li et al., 14 Oct 2025).
• Risk stratification in disease: In oncology, multimodal clocks (e.g., EpiCAge) outperform legacy clocks for age estimation and yield age-acceleration metrics that are robust predictors of all-cause mortality (HR per 5 y AgeAccel up to 1.113; $p<0.01$), supporting risk-adaptive treatment planning and survivorship care (Jiang et al., 10 Nov 2025).
• Surrogate endpoints for intervention: Multi-omics AgeAccel provides candidate surrogate measures for clinical trials in geroprotection, especially in mid-life windows where microbiome and immune axes undergo sharp transitions (Li et al., 14 Oct 2025).
• Precision gerontology: Weakly correlated omics clocks (e.g., BrainAge and MetaboAge, $r\approx0.16$) reflect distinct biological mechanisms; their combination yields improved survival prediction, motivating further expansion to include proteomics, exposomics, and additional imaging modalities (Mateus et al., 2024).
• Challenges and open questions: Deconvolving mutually trained omics clocks, orthogonalizing to chronological age, managing batch effects, and translating high-dimensional signatures into cost-effective panels remain active areas of method development.

The multi-omics aging clock paradigm is distinguished by its capacity for systemic age quantification, heterogeneity mapping, and actionable risk stratification, substantiated by high predictive accuracy and empirical validation across multiple population cohorts (Li et al., 14 Oct 2025, Jiang et al., 10 Nov 2025, Pridham et al., 2023, Mateus et al., 2024).